Sci-B-VacTM vs ENGERIX-B vaccines for hepatitis B virus in patients with inflammatory bowel diseases: A randomised controlled trial

Ohad Etzion, Victor Novack, Yael Perl, Olga Abel, Doron Schwartz, Daniella Munteanu, Naim Abufreha, Gil Ben-Yaakov, Eyal D. Maoz, Alex Moshaklo, Vitaly Dizingf, Alex Fich

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Background and Aims: Response rate to second-generation hepatitis B virus vaccines is relatively low in patients with inflammatory bowel diseases compared with the general healthy population. We compared the efficacy and safety of a third- vs a second-generation hepatitis B virus vaccine in a group of patients with inflammatory bowel diseases treated with immunosuppressive medications. Methods: Prospective, randomised, single-blind, controlled study. Eligible patients were randomly assigned to receive one of two vaccines, ENGERIX-B or Sci-B-Vac. The vaccines were administered in three doses at 0, 1, and 6 months. The primary endpoint was defined as the titre of anti-hepatitis B S [HBs] antibodies following the standard three-dose hepatitis B virus vaccination schedule. Results: A total of 72 patients complied with study protocol [37 and 35 patients in the ENGERIX-B and Sci-B-Vac groups, respectively]. Overall, 75% of the cohort seroconverted. The primary endpoint was met in 81.1% in the ENGERIX-B group and 68.6% in the Sci-B-Vac group [p = 0.22]. Patients in the Sci-B-Vac group showed a statistically significant decreased seroconversion rate compared with the ENGERIX-B group, with use of tumour necrosis factor [TNF] alpha inhibitors [p = 0.03], and higher degree of disease activity [p = 0.03]. Conclusions: Overall seroconversion rate in our cohort was higher than in previous reports in the literature, possibly due to a low disease activity state in the majority of participants. Thirdgeneration hepatitis B virus vaccines showed no apparent advantage over standard of care vaccine in this patient group.

Original languageEnglish
Pages (from-to)905-912
Number of pages8
JournalJournal of Crohn's and Colitis
Issue number8
StatePublished - 1 Jan 2016
Externally publishedYes


  • Hepatitis B virus vaccine
  • Immunosuppression
  • Inflammatory bowel disease

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Sci-B-VacTM vs ENGERIX-B vaccines for hepatitis B virus in patients with inflammatory bowel diseases: A randomised controlled trial'. Together they form a unique fingerprint.

Cite this